Publications
- Ambrisentan, selective endothelin receptor ETa antagonist, in the treatment of pulmonary arterial hypertension2010 | First Faculty of Medicine
- Ambrisentan in the treatment of pulmonary arterial hypertension2009 | First Faculty of Medicine
- Pulmonary arterial hypertension +42009 | First Faculty of Medicine
- Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension2024 | Publication without faculty affiliation
- Children's pneumology2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport, Third Faculty of Medicine
- Case--report: Paget--Schrötter syndrome as a cause of chronic thromboembolic pulmonary hypertension2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Catheter ablation of atrial fibrillation and atrial tachycardia in patients with pulmonary hypertension: a randomized study2023 | First Faculty of Medicine
- From venous thromboembolism to chronic thromboembolic pulmonary disease2023 | First Faculty of Medicine
- Current advances in the treatment of chronic pulmonary hypertension2023 | First Faculty of Medicine
Loading network view...